Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a $14.00 price objective on the stock.

A number of other brokerages have also weighed in on VYGR. Wedbush dropped their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, November 10th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Finally, Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Price Performance

Shares of VYGR opened at $5.64 on Thursday. The firm has a market capitalization of $308.11 million, a PE ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a 1-year low of $5.59 and a 1-year high of $11.72. The company’s fifty day moving average price is $6.62 and its 200-day moving average price is $7.50.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the previous year, the company earned ($0.59) earnings per share. As a group, research analysts anticipate that Voyager Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 6.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VYGR. BNP Paribas Financial Markets raised its position in shares of Voyager Therapeutics by 198.6% during the 1st quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after purchasing an additional 32,437 shares during the last quarter. Empowered Funds LLC raised its position in shares of Voyager Therapeutics by 8.2% during the 1st quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock worth $367,000 after purchasing an additional 2,975 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Voyager Therapeutics during the 1st quarter worth about $101,000. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 27.8% during the 1st quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Voyager Therapeutics by 10.1% during the 1st quarter. Acadian Asset Management LLC now owns 459,850 shares of the company’s stock worth $4,280,000 after purchasing an additional 42,029 shares during the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.